AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03232476 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Upper extremity voluntary loading
Description: Subjects who are prescribed teriparatide by their healthcare provider may enroll in this study. The study intervention consists of loading one upper extremity. Subjects will be trained on how to perform the upper extremity exercises at home. Subjects will be expected to perform the exercises 3 days per week using one arm, with each session consisting of 100 loading cycles lasting a total of approximately 2 minutes each day.
Study NCT01148446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/mq IV, day 1
Study NCT01148446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/mq IV, day 1
Study NCT01148446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/mq IV, day1
Study NCT01148446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1,4 mg/mq (max 2 mg)IV, day 1
Study NCT01148446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 75 mg/mq IV, days 1-5
Study NCT01148446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/mq IV/PO, days 1-5
Study NCT01148446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50 mg/mq IV, day 1
Study NCT01148446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 5 mg/mq IV, day 1
Study NCT01148446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/mq IV, day 1
Study NCT01148446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 300 µg tot., SC; days 7-11
Study NCT03608943 — intervention group
Intervention type: OTHER
Intervention: There is no specific intervention other than an individual changing their treatment as part of their usual care
Description: There is no specific intervention other than an individual changing their treatment as part of their usual care
Study NCT05396742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Solution for infusion or injection, as applicable
Study NCT05396742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Solution for infusion
Study NCT04110847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JING CEIH SHERN YUAN EXTRACT PILL
Description: Oral use, 3#BID
Study NCT04110847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JING CEIH SHERN YUAN EXTRACT PILL
Description: Oral use, 3#BID
Study NCT02554539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial fluid aspiration
Description: Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
Study NCT04079270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Description: The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.
Study NCT04079270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition intervention
Description: The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.
Study NCT03548558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group sessions
Description: Mother-child dyads in Arm 1 households will receive biweekly ECD sessions for a total of 16 sessions over 8 months. CHVs will record attendance at each session. To maximize participation, prior to each session the CHVs will send a short message service (SMS) mobile phone reminder of the session's topic, time and location to all participants.
Study NCT03548558 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group sessions
Description: Mother-child dyads in Arm 1 households will receive biweekly ECD sessions for a total of 16 sessions over 8 months. CHVs will record attendance at each session. To maximize participation, prior to each session the CHVs will send a short message service (SMS) mobile phone reminder of the session's topic, time and location to all participants.
Study NCT03548558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group+Home sessions
Description: Households in Arm 2 will receive a total of 16 sessions with identical content similar to Arm 1, but 4 of those sessions will replace group sessions held at the level of villages for personalized home visits, in which the CHV will visit each participant household to deliver these sessions. These home visits will cover identical material and topics as the group sessions in Arm 1 villages, but will be delivered on a personalized basis in the home of the mother and child. Personal barriers to the practices will be discussed and an active resolution strategy developed in concert with the CHV.
Study NCT03548558 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group+Home sessions
Description: Households in Arm 2 will receive a total of 16 sessions with identical content similar to Arm 1, but 4 of those sessions will replace group sessions held at the level of villages for personalized home visits, in which the CHV will visit each participant household to deliver these sessions. These home visits will cover identical material and topics as the group sessions in Arm 1 villages, but will be delivered on a personalized basis in the home of the mother and child. Personal barriers to the practices will be discussed and an active resolution strategy developed in concert with the CHV.
Study NCT03548558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster sessions
Description: After the end of the 16 biweekly sessions (phase 1), we will re-randomize across the 40 intervention villages, stratified by Arms 1 and 2, and half of each of Arm 1 and Arm 2 villages will receive group booster visits every other month for the period between end-line and follow-up surveys. This will constitute Phase 2 of the study.
Study NCT03548558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers invited
Description: During phase 1's 16 biweekly sessions, in half of Arm 1 and Arm 2 villages (20 total), fathers will additionally be invited to attend the 16 sessions. Separate father-only sessions will be held for 4 of the 16 sessions. This randomization will end after phase 1.
Study NCT04519892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDRC
Description: Personalized depression risk communication.
Study NCT04519892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PDRC
Description: Personalized depression risk communication.
Study NCT04519892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coach guidance
Description: Coaching service to guide the understanding of PDRC and answer questions.
Study NCT03431571 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ReLEx SMILE
Description: the VisuMax femtosecond laser is used to cut a thin layer of corneal tissue that is removed through a small cut in the cornea
Study NCT04479566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate 250 MG
Description: Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
Study NCT04479566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate 500 MG
Description: Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
Study NCT00783094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Description: oral, daily
Study NCT00783094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Description: oral, daily
Study NCT00783094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, daily
Study NCT01941407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
Study NCT03962205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral life style intervention
Description: Cognitive Behavioral life-style modification: The intervention will be composed of 12 weekly sessions. Each session will last about two hours and will be administered in a group setting (maximum 20 participants). During the first two sessions, a clinician will introduce the program to the participants and motivate them to make life-style changes.In the next eight sessions a dietician will provide participants with basics of nutrition and will coach them to use a structured diary to monitor their eating behavior and physical activity. Next, a physician will introduce to the patients various weight loss surgeries in terms of the adverse events, indications and effects of each option.The last session will be held by a psychologist and will focus on providing participants with useful strategies to promote healthy eating habits and physical activity, including problem solving and goal setting.
Study NCT03962205 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cognitive-behavioral life style intervention
Description: Cognitive Behavioral life-style modification: The intervention will be composed of 12 weekly sessions. Each session will last about two hours and will be administered in a group setting (maximum 20 participants). During the first two sessions, a clinician will introduce the program to the participants and motivate them to make life-style changes.In the next eight sessions a dietician will provide participants with basics of nutrition and will coach them to use a structured diary to monitor their eating behavior and physical activity. Next, a physician will introduce to the patients various weight loss surgeries in terms of the adverse events, indications and effects of each option.The last session will be held by a psychologist and will focus on providing participants with useful strategies to promote healthy eating habits and physical activity, including problem solving and goal setting.
Study NCT03962205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: wellbeing intervention
Description: This program will consist of 4 weekly group-based sessions and each meeting will last about two hours. During the sessions, participants will be coached how to self-monitor their well-being episodes in everyday life, especially those associated with life-style change, by means of a structured diary. Patients will be then ecounraged to discuss their well-being experiences during group sessions, focusing on dysfunctional thoughts/beliefs interrupting them, fostering the identification of more functional thoughts. The psychologist will also teach them how to promote well-being situations through behavioral exercises and will introduce to the participants relevant psychological well-being dimensions (based on Carol Ryff's multidimensional model) associated with patients' experiences emerged during the treatment.
Study NCT03962205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment as usual
Description: The treatment as usual will involve any recommendation given to the participants by their physicians, including diet, physical activity and medication.
Study NCT03962205 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: treatment as usual
Description: The treatment as usual will involve any recommendation given to the participants by their physicians, including diet, physical activity and medication.
Study NCT03981783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best available care (BAC)
Description: Eligible patients are assigned to a standard pulmonary rehabilitation program
Study NCT03981783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TH)
Description: Eligible patients are assigned to a pulmonary telerehabilitation program
Study NCT03840538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Product - Cap
Description: probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus
Study NCT03840538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Product - Cap
Description: probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus
Study NCT02869386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STEMO
Description: STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure Management (choice of drug at discretion of treating physician), use telemedicine for further expertise as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
Study NCT02869386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular care
Description: A regular ambulance, the comparator intervention, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
Study NCT02517775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry 320
Description: Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
Study NCT02517775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry 640
Description: Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
Study NCT02517775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry 960
Description: Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
Study NCT02517775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry 1280
Description: Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
Study NCT02517775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry 1600
Description: Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
Study NCT02517775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cranberry deprived supplement
Description: Cranberry deprived supplement Acute intake of 500 mL (1x daily)
Study NCT02669017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-402
Description: intravenous infusion
Study NCT02498639 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous balloon aortic valvuloplasty
Description: Percutaneous BAV is performed according to the standard retrograde technique. The measurement of the trans-aortic gradient is given by two catheters placed one in the left ventricle, the other in ascending aorta. An extra stiff wire is placed in the left ventricular cavity. A balloon (size fitting the valve annulus) is inserted over the wire and a series of three inflations is performed at nominal pressure.~The procedure terminates in case of:~1. Reduction of the mean aortic gradient ≥50%.~2. Aortic pressure drop during the inflations, indicative of valve orifice sealing.~3. Intraprocedural complication.~4. Poor compliance of the patient. If none is met, the balloon is changed with a bigger one and a new series of three inflations performed. Aortic gradient is finally recorded.
Study NCT04621370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.
Study NCT04621370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: Oxaliplatin 85mg/m2 delivered intravenously as per institutional standard on Day 1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil infusion 2400mg/m2 delivered intravenously over 46 hours continuously as per institutional standard following bolus 5-fluorouracil.
Study NCT04621370 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short Course Radiotherapy (Arm A)
Description: 25 Gray of photon radiation treatment delivered over 5 fractions.
Study NCT04621370 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long course chemoradiation (Arm B)
Description: 50 Gray of photon radiation treatment delivered over 25 fractions.
Study NCT04621370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.
Study NCT02018822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: urethane dimethacrylate
Description: Experimental urethane dimethacrylate resin based composite resin for teeth used with prime and Bond Elect bonding agent
Study NCT02018822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPH3
Description: light-cured resin composite for teeth
Study NCT02018822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esthet-X HD
Description: light cured resin composite for teeth made by Dentsply Caulk
Study NCT00152542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: 1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
Study NCT00152542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No iNO given for days 1-7
Study NCT00811135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
Study NCT00811135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 bid po on days 1-14 of each 3-week cycle
Study NCT00811135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: 8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
Study NCT00428974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 1mg
Description: CF101 1 mg q12 hours for 12 weeks
Study NCT00428974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 2mg
Description: CF101 2 mg q12 hours for 12 weeks
Study NCT00428974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 4mg
Description: CF101 4 mg q12 hours for 12 weeks
Study NCT00428974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets q12 hours for 12 weeks
Study NCT03335332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: The exercise groups will receive identical exercise prescription for the first two months of the intervention, after which the HIE group will incorporate HIIT in their exercise regimen. The reason for this approach is to include a period of general conditioning and progressively increase intensity prior to submitting volunteers to HIE. This approach considers participant safety as arrhythmias may be uncovered during the first two months of MIE training. It will also improve participant compliance by increasing exercise self-efficacy and confidence prior to commencing HIIT.
Study NCT03335332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise
Description: A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions in both exercise groups (MIE and HIE) will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
Study NCT00832728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard hospital protocol for the treatment of acute liver failure
Study NCT00832728 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard hospital protocol for the treatment of acute liver failure
Study NCT00832728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELAD®
Description: ELAD therapy
Study NCT03239821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VIPUN Balloon Catheter 0.1 deflated
Description: deflation balloon
Study NCT03239821 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VIPUN Balloon Catheter 0.1 deflated
Description: deflation balloon
Study NCT03239821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Phosphate
Description: 58.8 mg codeïne phosphate
Study NCT03239821 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sirupus Simplex
Study NCT03239821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sirupus Simplex
Study NCT03239821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VIPUN Balloon Catheter 0.1 inflated
Description: VIPUN Balloon Catheter 0.1 inflated